查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1617792

體外診斷市場：按組件、技術、檢體、應用和最終用戶分類 - 2025-2030 年全球預測

In-Vitro Diagnostics Market by Component (Data Management Software & Services, Instruments, Reagents & Kits), Technology (Clinical Chemistry, Coagulation & Hemostasis, Hematology), Specimen, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年體外診斷市值為1,090.5億美元，預計到2024年將達到1,150.4億美元，複合年成長率為6.11%，到2030年將達到1,652.7億美元。

體外診斷 (IVD) 包括用於在體外受控環境中檢體人體樣本（例如血液、組織和其他體液）的醫療設備和測試方法。對體外診斷藥物的需求源於它們在診斷疾病、監測健康狀況、預測疾病進展和確定治療策略方面發揮的重要作用。體外診斷用於多種領域，包括感染疾病、腫瘤學、心臟病學、內分泌學和基因檢測。最終用戶主要包括醫院、診斷實驗室、學術機構和就地檢驗中心。市場成長的主要驅動力包括技術進步、慢性病和感染疾病患者病率的增加、對個人化醫療的需求不斷增加以及對疾病早期診斷的認知不斷提高。人工智慧和自動化在診斷中的整合有望提高準確性和效率，並帶來重大機會。此外，尤其是由於新冠肺炎 (COVID-19) 大流行，家庭檢測的轉變為開發方便用戶使用型快速檢測提供了機會。然而，嚴格的監管要求、與先進診斷相關的高成本以及報銷限制正在阻礙市場成長。其他挑戰包括來自替代疾病檢測方法的競爭以及將新技術融入現有系統的複雜性。對於公司而言，分子診斷、次世代定序和攜帶式診斷設備等領域的創新提供了一個有希望的成長途徑。投資研發以提高測試特異性和靈敏度以及開發具有成本效益的技術對於市場擴張至關重要。此外，主要相關人員之間的合作和夥伴關係可以簡化創新和市場滲透。市場是動態的，其特點是技術不斷發展和競爭格局不斷變化，需要不斷適應和策略變革。公司必須積極應對監管挑戰，並利用數位醫療解決方案等新興趨勢來維持和擴大其市場佔有率。

主要市場統計
基準年[2023] 1090.5億美元
預測年份 [2024] 1150.4億美元
預測年份 [2030] 1652.7億美元
複合年成長率（%） 6.11%

市場動態：快速發展的體外診斷市場的關鍵市場洞察

供需的動態交互作用正在改變體外診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病及感染疾病率增加
    • 隨著伴同性診斷的普及，對個人化治療的關注日益增加
    • 政府積極進行健康意識宣傳活動和體檢
  • 市場限制因素
    • 缺乏針對特定診斷測試的全面報銷政策
  • 市場機會
    • 隨著醫療保健基礎設施的發展，POC 測試範圍不斷擴大
    • 數位健康平台和診斷整合
  • 市場挑戰
    • 體外診斷的嚴格法規和核准流程

波特五力：駕馭體外診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解體外診斷市場的外部影響

外部宏觀環境因素在塑造體外診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解體外診斷市場的競爭狀況

體外診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣體外診斷市場供應商績效評估

FPNV定位矩陣是評估體外診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪 IVD 市場的成功之路

體外診斷市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病及感染疾病率增加
      • 日益關注個人化治療並增加伴同性診斷的引入
      • 政府對健康意識宣傳活動和檢測採取的有利方法
    • 抑制因素
      • 缺乏針對特定診斷測試的全面報銷政策
    • 機會
      • 擴大醫療基礎設施和擴大就地檢驗
      • 診斷和數位健康平台的整合
    • 任務
      • 與體外診斷相關的嚴格法規和核准流程
  • 市場區隔分析
    • 組成部分：儀器和試劑在體外診斷中的重要作用
    • 應用：體外診斷在癌症治療的創新應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章體外診斷市場：依組成部分

  • 資料管理軟體和服務
  • 裝置
  • 試劑和套件

第7章體外診斷市場：依技術分類

  • 臨床化學
    • 基礎代謝組
    • 電解質板
    • 血脂譜
    • 肝臟組
    • 腎臟概況
    • 特殊化學測試
    • 甲狀腺功能檢查
  • 凝血和止血
  • 血液學
  • 免疫化學
    • 酵素免疫分析法
      • 化學冷光免疫檢測
      • 免疫檢測
      • 螢光免疫分析法
    • 酵素連結免疫斑點測定
    • 免疫檢測
    • 快速測試
    • 蛋白質印跡法
  • 微生物學
  • 分子診斷
    • DNA定序與次世代定序
    • 交配
    • 恒溫核酸增幅技術
    • 微陣列
    • 聚合酵素鏈鎖反應
  • 尿液檢查

第8章 體外診斷標本市場

  • 血液、血清、血漿
  • 唾液
  • 尿

第9章體外診斷市場：依應用分類

  • 自體免疫疾病
  • 心臟病學
  • 糖尿病
  • 藥物測試
  • 愛滋病毒/愛滋病
  • 感染疾病
  • 腎臟病學
  • 腫瘤學

第 10 章 體外診斷市場：依最終使用者分類

  • 醫院和護理提供者
  • 研究所
  • 患者自查

第11章 北美和南美體外診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區體外診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲體外診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Biocare Medical 的先進抗原修復室 (ARC) 徹底改變了免疫組織化學
    • GenWorks Health 推出登革熱和瘧疾 IVD 檢測
    • Oxford Nanopore 與生物梅里埃簽署策略合作協議，開發創新的感染疾病診斷
  • 戰略分析和建議

公司名單

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • Adaptive Biotechnologies Corp
  • Agilent Technologies Inc.
  • Arkray Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Biomerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • EKF GmbH
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Hologic, Inc.
  • Illumina, Inc.
  • Menarini Diagnostics
  • Mindray Medical International Limited
  • Myriad Genetics, Inc.
  • Ortho-Clinical Diagnostics, Inc.
  • Qiagen GmbH
  • Randox Laboratories
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-434CCDA04D33

The In-Vitro Diagnostics Market was valued at USD 109.05 billion in 2023, expected to reach USD 115.04 billion in 2024, and is projected to grow at a CAGR of 6.11%, to USD 165.27 billion by 2030.

In-Vitro Diagnostics (IVD) encompasses medical devices and assays used to test specimens derived from the human body, such as blood, tissues, and other body fluids, outside the body in a controlled environment. The necessity for IVD arises from its critical role in diagnosing diseases, monitoring health, predicting disease progression, and guiding treatment decisions. Applications of IVD range across various domains, including infectious diseases, oncology, cardiology, endocrinology, and genetic testing. End-users primarily include hospitals, diagnostic laboratories, academic institutions, and point-of-care testing centers. Key market growth drivers include advancements in technology, an increasing prevalence of chronic and infectious diseases, the growing demand for personalized medicine, and heightened awareness of early disease diagnosis. The integration of artificial intelligence and automation in diagnostics presents a significant opportunity, promising enhanced accuracy and efficiency. Furthermore, the shift towards home-based testing especially poised by the COVID-19 pandemic, corroborates opportunities in developing user-friendly and rapid tests. However, market growth is hindered by stringent regulatory requirements, high costs associated with advanced diagnostics, and reimbursement constraints. Challenges also include the competition from alternative disease testing methodologies and the complexity of integrating novel technologies into existing systems. For businesses, innovation in areas such as molecular diagnostics, next-generation sequencing, and portable diagnostic devices offers promising growth avenues. Investing in research to enhance test specificity and sensitivity, and developing cost-effective technologies, are crucial for market expansion. Moreover, collaborations and partnerships among key stakeholders can streamline innovation and market penetration. The market is dynamic, characterized by continuous technological evolution and competitive landscape, necessitating continuous adaptation and strategy modulation. Businesses must remain proactive in addressing regulatory challenges and leverage emerging trends, such as digital healthcare solutions, to sustain and grow their market presence.

KEY MARKET STATISTICS
Base Year [2023] USD 109.05 billion
Estimated Year [2024] USD 115.04 billion
Forecast Year [2030] USD 165.27 billion
CAGR (%) 6.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic and infectious diseases
    • Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
    • Favourable government initiative for health awareness campaigns and screenings
  • Market Restraints
    • Lack of comprehensive reimbursement policies for certain diagnostic tests
  • Market Opportunities
    • Expansion of point-of-care testing coupled with growing healthcare infrastructure
    • Integration of diagnostics with digital health platforms
  • Market Challenges
    • Stringent regulations and approval processes associated with in vitro diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Vitro Diagnostics Market

A detailed market share analysis in the In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Vitro Diagnostics Market

A strategic analysis of the In-Vitro Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Data Management Software & Services, Instruments, and Reagents & Kits.
  • Based on Technology, market is studied across Clinical Chemistry, Coagulation & Hemostasis, Hematology, Immunochemistry, Microbiology, Molecular Diagnostics, and Urinalysis. The Clinical Chemistry is further studied across Basic Metabolic Panel, Electrolyte Panel, Lipid Profile, Liver Panel, Renal Profile, Specialty Chemical Tests, and Thyroid Function Panel. The Immunochemistry is further studied across Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assays, Radioimmunoassay, Rapid Test, and Western Blotting. The Enzyme-Linked Immunosorbent Assay is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, and Fluorescence Immunoassays. The Molecular Diagnostics is further studied across DNA Sequencing & Next-Generation Sequencing, Hybridization, Isothermal Nucleic Acid Amplification Technology, Microarray, and Polymerase Chain Reaction.
  • Based on Specimen, market is studied across Blood, Serum & Plasma, Saliva, and Urine.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiology, Diabetes, Drug Testing, HIV/Aids, Infectious Diseases, Nephrology, and Oncology.
  • Based on End User, market is studied across Hospitals & Care Providers, Laboratories, and Patient Self-Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and infectious diseases
      • 5.1.1.2. Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
      • 5.1.1.3. Favourable government initiative for health awareness campaigns and screenings
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of comprehensive reimbursement policies for certain diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of point-of-care testing coupled with growing healthcare infrastructure
      • 5.1.3.2. Integration of diagnostics with digital health platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approval processes associated with in vitro diagnostics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: The integral role of instruments, and reagents in in-vitro diagnostics
    • 5.2.2. Application: Revolutionizing application of in-vitro diagnostic in cancer care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In-Vitro Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Data Management Software & Services
  • 6.3. Instruments
  • 6.4. Reagents & Kits

7. In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Clinical Chemistry
    • 7.2.1. Basic Metabolic Panel
    • 7.2.2. Electrolyte Panel
    • 7.2.3. Lipid Profile
    • 7.2.4. Liver Panel
    • 7.2.5. Renal Profile
    • 7.2.6. Specialty Chemical Tests
    • 7.2.7. Thyroid Function Panel
  • 7.3. Coagulation & Hemostasis
  • 7.4. Hematology
  • 7.5. Immunochemistry
    • 7.5.1. Enzyme-Linked Immunosorbent Assay
      • 7.5.1.1. Chemiluminescence Immunoassays
      • 7.5.1.2. Colorimetric Immunoassays
      • 7.5.1.3. Fluorescence Immunoassays
    • 7.5.2. Enzyme-Linked Immunospot Assays
    • 7.5.3. Radioimmunoassay
    • 7.5.4. Rapid Test
    • 7.5.5. Western Blotting
  • 7.6. Microbiology
  • 7.7. Molecular Diagnostics
    • 7.7.1. DNA Sequencing & Next-Generation Sequencing
    • 7.7.2. Hybridization
    • 7.7.3. Isothermal Nucleic Acid Amplification Technology
    • 7.7.4. Microarray
    • 7.7.5. Polymerase Chain Reaction
  • 7.8. Urinalysis

8. In-Vitro Diagnostics Market, by Specimen

  • 8.1. Introduction
  • 8.2. Blood, Serum & Plasma
  • 8.3. Saliva
  • 8.4. Urine

9. In-Vitro Diagnostics Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiology
  • 9.4. Diabetes
  • 9.5. Drug Testing
  • 9.6. HIV/Aids
  • 9.7. Infectious Diseases
  • 9.8. Nephrology
  • 9.9. Oncology

10. In-Vitro Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Care Providers
  • 10.3. Laboratories
  • 10.4. Patient Self-Testing

11. Americas In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa In-Vitro Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry
    • 14.3.2. GenWorks Health launches IVD tests for dengue & malaria
    • 14.3.3. Oxford Nanopore and bioMerieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 10x Genomics, Inc.
  • 2. Abbott Laboratories
  • 3. Adaptive Biotechnologies Corp
  • 4. Agilent Technologies Inc.
  • 5. Arkray Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories Inc.
  • 8. Biomerieux SA
  • 9. Danaher Corporation
  • 10. DiaSorin S.p.A.
  • 11. EKF GmbH
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Grifols SA
  • 14. Hologic, Inc.
  • 15. Illumina, Inc.
  • 16. Menarini Diagnostics
  • 17. Mindray Medical International Limited
  • 18. Myriad Genetics, Inc.
  • 19. Ortho-Clinical Diagnostics, Inc.
  • 20. Qiagen GmbH
  • 21. Randox Laboratories
  • 22. Siemens AG
  • 23. Sysmex Corporation
  • 24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BASIC METABOLIC PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIPID PROFILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RENAL PROFILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIALTY CHEMICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT SELF-TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 244. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 254. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 263. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 272. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 274. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 283. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 284. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 286. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 290. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 292. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 293. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 294. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 295. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 296. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 299. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 301. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 302. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 303. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 304. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 305. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 308. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 310. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 311. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 312. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 313. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 314. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 317. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 318. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 319. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 320. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 321. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 322. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 323. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 326. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 328. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 329. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 330. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 331. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 332. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATIO